Breaking Down Barriers: How Understanding Celiac Disease Pathogenesis Informed the Development of Novel Treatments
- PMID: 31076989
- PMCID: PMC6586517
- DOI: 10.1007/s10620-019-05646-y
Breaking Down Barriers: How Understanding Celiac Disease Pathogenesis Informed the Development of Novel Treatments
Abstract
For decades, the pathogenesis of a variety of human diseases has been attributed to increased intestinal paracellular permeability even though scientific evidence supporting this hypothesis has been tenuous. Nevertheless, during the past decade, there have been a growing number of publications focused on human genetics, the gut microbiome, and proteomics, suggesting that loss of mucosal barrier function, particularly in the gastrointestinal tract, may substantially affect antigen trafficking, ultimately causing chronic inflammation, including autoimmunity, in genetically predisposed individuals. The gut mucosa works as a semipermeable barrier in that it permits nutrient absorption and also regulates immune surveillance while retaining potentially harmful microbes and environmental antigens within the intestinal lumen. Celiac disease (CD), a systemic, immune-mediated disorder triggered by gluten in genetically susceptible individuals, is associated with altered gut permeability. Pre-clinical and clinical studies have shown that gliadin, a prolamine component of gluten that is implicated in CD pathogenesis, is capable to disassembling intercellular junctional proteins by upregulating the zonulin pathway, which can be inhibited by the zonulin antagonist larazotide acetate. In this review, we will focus on CD as a paradigm of chronic inflammatory diseases in order to outline the contribution of gut paracellular permeability toward disease pathogenesis; moreover, we will summarize current evidence derived from available clinical trials of larazotide acetate in CD.
Keywords: Antigen trafficking; Autoimmunity; Gut permeability; Inflammation; Tight junctions; Zonulin.
Conflict of interest statement
Conflict of interest: Dr. Fasano is co-founder and stock holder of Alba Therapeutics, a company developing treatments complementary to the gluten free diet by exploiting gut permeability; Dr. Valitutti has no conflict of interest.
Figures



Similar articles
-
Intestinal Barrier Function in Gluten-Related Disorders.Nutrients. 2019 Oct 1;11(10):2325. doi: 10.3390/nu11102325. Nutrients. 2019. PMID: 31581491 Free PMC article. Review.
-
Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines.Scand J Gastroenterol. 2006 Apr;41(4):408-19. doi: 10.1080/00365520500235334. Scand J Gastroenterol. 2006. PMID: 16635908
-
Effect of gliadin on permeability of intestinal biopsy explants from celiac disease patients and patients with non-celiac gluten sensitivity.Nutrients. 2015 Feb 27;7(3):1565-76. doi: 10.3390/nu7031565. Nutrients. 2015. PMID: 25734566 Free PMC article. Clinical Trial.
-
All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases.F1000Res. 2020 Jan 31;9:F1000 Faculty Rev-69. doi: 10.12688/f1000research.20510.1. eCollection 2020. F1000Res. 2020. PMID: 32051759 Free PMC article. Review.
-
Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3.Gastroenterology. 2008 Jul;135(1):194-204.e3. doi: 10.1053/j.gastro.2008.03.023. Epub 2008 Mar 21. Gastroenterology. 2008. PMID: 18485912 Free PMC article.
Cited by
-
Novel Drug Therapeutics in Celiac Disease: A Pipeline Review.Drugs. 2022 Oct;82(15):1515-1526. doi: 10.1007/s40265-022-01784-2. Epub 2022 Oct 17. Drugs. 2022. PMID: 36251239 Review.
-
Gluten Degradation by the Gut Microbiota of Ulcerative Colitis Patients.Microorganisms. 2022 Dec 21;11(1):12. doi: 10.3390/microorganisms11010012. Microorganisms. 2022. PMID: 36677307 Free PMC article.
-
Nutritional Quality, Antioxidant, Microstructural and Sensory Properties of Spontaneously Fermented Gluten-Free Finger Millet Biscuits.Foods. 2022 Apr 27;11(9):1265. doi: 10.3390/foods11091265. Foods. 2022. PMID: 35563992 Free PMC article.
-
Seroprevalence of Antitransglutaminase and Antiendomysium Antibodies in Adult Colombian Blood Bank Donors.Can J Gastroenterol Hepatol. 2020 Nov 30;2020:7541941. doi: 10.1155/2020/7541941. eCollection 2020. Can J Gastroenterol Hepatol. 2020. PMID: 33335872 Free PMC article.
-
The Contribution of the Intestinal Microbiota to the Celiac Disease Pathogenesis along with the Effectiveness of Probiotic Therapy.Microorganisms. 2023 Nov 23;11(12):2848. doi: 10.3390/microorganisms11122848. Microorganisms. 2023. PMID: 38137992 Free PMC article. Review.
References
-
- Husby S Koletzko S, Korponay-Szabo IR et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr. 2012;54:136–60. - PubMed
-
- Catassi C, Kryszak D, Bhatti B et al. Natural history of celiac disease autoimmunity in a USA cohort followed since 1974. Ann Med. 2010; 42:530–538. - PubMed
-
- Lionetti E, Castellaneta S, Francavilla R et al. Introduction of gluten, HLA status, and the risk of celiac disease in children. N Engl J Med. 2014; 371:1295–303. - PubMed
-
- Fasano A Celiac disease - how to handle a clinical chameleon. N Engl J Med 2003; 348:2568–70 - PubMed
-
- Tapsas D, Hollén E, Stenhammar L et al. The clinical presentation of coeliac disease in 1030 Swedish children: Changing features over the past four decades. Dig Liver Dis 2016; 48:16–22. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous